HIF-α, a gender independent transcription factor

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2391-2393

  Le, Quynh Thu ^a   Giaccia, Amato J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN; ANDROSTANOLONE; ANTIANDROGEN; AROMATIC HYDROCARBON RECEPTOR; BICALCULAMIDE; CYTOKINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUTAMIDE; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1BETA; INSULIN; NEU DIFFERENTIATION FACTOR; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; RAPAMYCIN; SOMATOMEDIN BINDING PROTEIN 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; AUTOCRINE EFFECT; BLOOD FLOW; BRACHYTHERAPY; CANCER STAGING; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; DNA BINDING; EDITORIAL; GENDER; GENE MUTATION; HUMAN; HYDROXYLATION; HYPOXIA; ONCOGENE NEU; OXYGEN TENSION; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; RADIOBIOLOGY; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANOXIA; DISEASE PROGRESSION; DNA; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INSULIN; MALE; NEOPLASM TRANSPLANTATION; NEOPLASMS; OXYGEN; PROTEIN BINDING; SEX FACTORS; TRANSCRIPTION FACTORS;

EID: 0037817621     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (25)

1. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer statistics, 2002. CA Cancer J. Clin., 52: 23-47, 2002.
2. Brown, J. M., and Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58: 1408-1416, 1998.
3. Brizel, D. M., Dodge, R. K., Clough, R. W., and Dewhirst, M. W. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol., 53: 113-117, 1999.
4. Fyles, A. W., Milosevic, M., Wong, R., Kavanagh, M. C., Pintilie, M., Sun, A., Chapman, W., Levin, W., Manchul, L., Keane, T. J., and Hill, R. P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol., 48: 149-156, 1998.
5. 2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology, 60: 634-639, 2002.
6. Leith, J. T. In vitro radiation sensitivity of the LNCaP prostatic tumor cell line. Prostate, 24: 119-124, 1994.
7. 2 study. Cancer (Phila.), 89: 2018-2024, 2000.
8. Parker, C. C., Milosevic, A., Toi, A., Sweet, J., Panzarella, T., Syed, A., Bristow, R., Catton, C., Hill, R., and Warde, P. A polarographic electrode study of tumor oxygenation in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 51 (Suppl. 1): 78-79, 2001.
9. Cvetkovic, D., Movsas, B., Dicker, A. P., Hanlon, A. L., Greenberg, R. E., Chapman, J. D., Hanks, G. E., and Tricoli, J. V. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology, 57: 821-825, 2001.
10. Stewart, R. J., Panigrahy, D., Flynn, E., and Folkman, J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J. Urol., 165: 688-693, 2001.
11. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA, 95: 7987-7992, 1998.
12. Bruick, R. K., and McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science (Wash. DC), 294: 1337-1340. 2001.
13. Semenza, G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol., 64: 993-998, 2002.
14. 2-dependent degradation domain of hypoxia inducible factor-1α (HIF-1α). J. Cancer Res. Clin. Oncol., 128: 358-362, 2002.
15. McMenamin, M. E., Soung, P., Perera, S., Kaplan, I., Loda, M., and Sellers, W. R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res., 59: 4291-4296, 1999.
16. Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., Stokoe, D., and Giaccia, A. J. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev., 14: 391-396, 2000.
17. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., Simons, J. W., and Semenza, G. L. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/ phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res., 60: 1541-1545, 2000.
18. Mabjeesh, N. J., Willard, M. T., Frederickson, C. E., Zhong, H., and Simons, J. W. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/AKT in prostate cancer cells. Clin. Cancer Res., 9: 2416-2425, 2003.
19. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., and Semenza, G. L. HER2(neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol., 21: 3995-4004, 2001.
20. Di Lorenzo, G., Tortora, G., D'Armiento, F. P., De Rosa, G., Staibano, S., Autorino, R., D'Armiento, M., De Laurentiis, M., De Placido, S., Catalano, G., Bianco, A. R., and Ciardiello, F. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res., 8: 3438-3444, 2002.
21. Zelzer, E., Levy, Y., Kahana, C., Shilo, B. Z., Rubinstein, M., and Cohen, B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1αARNT. EMBO J., 17: 5085-5094, 1998.
22. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Hittmair, A., Zhang, J., Thurnher, M., Bartsch, G., and Klocker, H. Regulation of prostatic growth and function by peptide growth factors. Prostate, 28: 392-405, 1996.
23. Sherwood, E. R., Van Dongen, J. L., Wood, C. G., Liao, S., Kozlowski, J. M., and Lee, C. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br. J. Cancer, 77: 855-861, 1998.
24. Rubenstein, M., Mirochnik, Y., Chou, P., and Guinan, P. Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides. Methods Find. Exp. Clin. Pharmacol., 20: 825-831, 1998.
25. Karashima, T., Sweeney, P., Slaton, J. W., Kim, S. J., Kedar, D., Izawa, J. I., Fan, Z., Pettaway, C., Hicklin, D. J., Shuin, T., and Dinney, C. P. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin. Cancer Res., 8: 1253-1264, 2002.